Author

J. Baggenstos

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:differential expression· 1 Organism:E. coli· 1 Approach:genetic perturbation / CRISPR· 1 Assay:metagenomics· 1 Organism:mouse· 1

Frequent Co-Authors

M. J. Loessner· 3 shared S. Kilcher· 3 shared C. I. Matter· 2 shared J. Du· 2 shared L. Hunold· 2 shared L. Leitner· 2 shared M. Dunne· 2 shared P. Piffaretti· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

M. J. Loessner

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CRISPR-Cas9 enables efficient genome engineering of the strictly lytic, broad host-range staphylococcal bacteriophage K

J. Fernbach, J. Baggenstos, J. Riedo, S. McCallin, M. J. Loessner, S. Kilcher

This paper develops a CRISPR-Cas9-based platform for engineering Twortvirinae phages to create reporter phages for detecting Staphylococcus aureus in clinical and environmental samples.

bioRxiv · Mar 19, 2024Bioengineering

Engineered reporter phages for rapid detection of Escherichia coli, Klebsiella spp., and Enterococcus spp. in urine

S. Meile, J. Du, S. Staubli, S. Grossmann, H. Koliwer-Brandl, P. Piffaretti, L. Leitner, C. I. Matter, J. Baggenstos, L. Hunold, S. Milek, C. Guebeli, M. Kozomara-Hocke, V. Neumeier, A. Botteon, , S. Kilcher

This study develops a rapid phage-based diagnostic assay to detect E. coli, Klebsiella spp., and Enterococcus spp. in urine with high sensitivity and specificity within 5 hours.

bioRxiv · Nov 23, 2022 · PreprintMicrobiology

Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors

J. Du, S. Meile, J. Baggenstos, T. Jaeggi, P. Piffaretti, L. Hunold, C. I. Matter, L. Leitner, T. M. Kessler, M. J. Loessner, S. Kilcher, M. Dunne

This paper develops heterologous effector phage therapeutics (HEPTs) to enhance bacteriophage treatment of UTIs by delivering colicin-like effectors that suppress resistance and improve bacterial killing.

bioRxiv · Mar 9, 2022 · PreprintBioengineering